Upadacitinib in Crohn's disease.

Introduction: The small molecule and oral selective and reversible Janus kinase (JAK) inhibitor upadacitinib has been approved for the treatment of moderate to severe active Crohn's disease (CD) in adult patients since April 2023 by EMA/FDA.

Areas Covered: The approval is based on the two induction studies a maintenance study showing that upadacitinib induction and maintenance therapy was superior to placebo. The approval of upadacitinib in CD expands the therapeutic armamentarium for the management of inflammatory bowel diseases (IBD).

Investigating the role of residential migration history on the relationship between attachment and sense of belonging: A SEM approach.

With the rate of both domestic and international migration steadily increasing, the psychological impact of residential migration remains largely unexplored. Attachment, the emotional bond we establish with those close to us, and sense of belonging, the feeling of connectedness to a community, may be vulnerable to frequent migration. This study investigates the association between individuals' early attachment style, sense of belonging, and migration history.

[Biologics in inflammatory bowel diseases].

Background: In addition to conventional anti-inflammatory treatment for chronic inflammatory bowel disease (IBD), there has been an evolution of new treatment options over the past 20 years. Already approved biologics provide multiple treatment alternatives but also make the treatment algorithms more complex. This development results in a substantial improvement in patient care.